Scope Fluidics SA (SCP) - Total Liabilities
Based on the latest financial reports, Scope Fluidics SA (SCP) has total liabilities worth zł26.24 Million PLN (≈ $7.22 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Scope Fluidics SA operating cash flow efficiency to assess how effectively this company generates cash.
Scope Fluidics SA - Total Liabilities Trend (2015–2024)
This chart illustrates how Scope Fluidics SA's total liabilities have evolved over time, based on quarterly financial data. Check Scope Fluidics SA (SCP) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Scope Fluidics SA Competitors by Total Liabilities
The table below lists competitors of Scope Fluidics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ayes Celik Hasir ve Cit Sanayi AS
IS:AYES
|
Turkey | TL2.24 Billion |
|
BTCS Inc
NASDAQ:BTCS
|
USA | $73.45 Million |
|
CVC Income & Growth Limited
LSE:CVCE
|
UK | €316.00K |
|
Tethys Petroleum Ltd
V:TPL
|
Canada | CA$31.84 Million |
|
Piscines Desjoyaux SA
PA:ALPDX
|
France | €58.08 Million |
|
Prime Securities Limited
NSE:PRIMESECU
|
India | Rs291.90 Million |
|
Rapid Micro Biosystems Inc
NASDAQ:RPID
|
USA | $41.65 Million |
|
09women Co. Ltd.
KQ:366030
|
Korea | ₩5.93 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Scope Fluidics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Scope Fluidics SA.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scope Fluidics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scope Fluidics SA (2015–2024)
The table below shows the annual total liabilities of Scope Fluidics SA from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł26.52 Million ≈ $7.30 Million |
+28.99% |
| 2023-12-31 | zł20.56 Million ≈ $5.66 Million |
+55.96% |
| 2022-12-31 | zł13.18 Million ≈ $3.63 Million |
-65.45% |
| 2021-12-31 | zł38.15 Million ≈ $10.50 Million |
+364.13% |
| 2020-12-31 | zł8.22 Million ≈ $2.26 Million |
+14.39% |
| 2019-12-31 | zł7.19 Million ≈ $1.98 Million |
+552.49% |
| 2018-12-31 | zł1.10 Million ≈ $303.10K |
-39.28% |
| 2017-12-31 | zł1.81 Million ≈ $499.17K |
+103.45% |
| 2016-12-31 | zł891.52K ≈ $245.36K |
-67.80% |
| 2015-12-31 | zł2.77 Million ≈ $761.91K |
-- |
About Scope Fluidics SA
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.